Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Infectious Diseases

Building Your Foundation: Understanding Talaromycosis

At a Glance

Talaromycosis is a serious fungal infection caused by Talaromyces marneffei, usually acquired by inhaling environmental spores in parts of Southeast Asia, southern China, and the Indian subcontinent. It is not spread from person to person and is most severe in people with weakened immune systems.

Receiving a diagnosis of talaromycosis (formerly known as penicilliosis) can be a profound shock. It is a severe, systemic fungal infection that often appears suddenly, and the realization that a fungus is circulating through your body can feel overwhelming [1]. Understanding exactly what this organism is and how it behaves is a vital first step in regaining a sense of control over your health.

What is Talaromyces marneffei?

The cause of this infection is a fungus called Talaromyces marneffei. It belongs to a unique group of fungi known as thermally dimorphic [2]. “Dimorphic” means the fungus has two different forms or shapes, which it switches between based on the temperature:

  • In the Environment (Cooler Temperatures): At temperatures around 25°C (77°F), it grows as a multicellular mold with thread-like structures called hyphae that produce tiny spores called conidia [2][3].
  • In the Body (Warmer Temperatures): When those spores enter the human body (which is roughly 37°C or 98.6°F), the fungus undergoes a dramatic transformation. It turns into an invasive yeast form—small, single cells that divide by splitting in half (fission) [2].

This ability to change shape is a survival strategy that allows the fungus to adapt to the harsh environment inside a human host and spread through the bloodstream [4][5].

Who is Most Affected?

Talaromycosis is highly geographic. It is endemic (meaning it is naturally found) in Southeast Asia, Southern China, and parts of the Indian subcontinent [6][7]. While most cases occur in people currently living in these areas, it is also diagnosed in travelers or those with a history of residence in these regions, sometimes long after the initial exposure [8].

The fungus is an opportunistic pathogen, meaning it typically only causes severe disease in people with weakened immune systems. The most common groups at risk include:

  • Advanced HIV: Historically, the vast majority of cases have been in people living with HIV who have very low CD4 counts (a measure of immune strength), often below 100 cells/µL [9][10].
  • Non-HIV Immunocompromised: Increasingly, the infection is seen in people without HIV who have other immune challenges. This includes individuals with autoimmune disorders, organ or stem-cell transplant recipients, and those with rare conditions like anti-interferon-gamma (IFN-γ) autoantibodies—a condition where the body mistakenly attacks its own immune signaling proteins [11][12].
  • Genetic Factors: Some people may have inherited “inborn errors of immunity” (genetic mutations) that make them specifically vulnerable to this type of fungus [13][14].

How the Fungus Evades Your Defenses

Once the fungus enters the body, research shows it has evolved sophisticated ways to hide from your immune system. It can target macrophages, which are the “first responder” cells meant to eat and destroy invaders [5].

Instead of being destroyed, the yeast form of the fungus can actually survive and multiply inside your immune cells [5]. While these are mechanisms seen in research studies rather than factors that decide your treatment, it does this by:

  • Changing Its Appearance: The switch to the yeast form helps it survive the stress of being inside an immune cell [15].
  • Suppressing Alarms: The fungus produces proteins (like Mp1p) that can deactivate the “danger signals” your immune cells would normally send out to recruit help [16].
  • Blunting the Response: It can prompt immune cells into a “quiet” state (known as M2-like polarization), preventing them from launching an effective attack [17].

How You Contracted It

It is important to know that talaromycosis is not contagious. You cannot catch it from another person through casual contact, coughing, or sharing a household, and there is no need for household prophylaxis [18].

The infection is environmental. Most people contract it by inhaling the microscopic spores (conidia) from the environment, likely from soil or decaying vegetation [19][20].

Bamboo rats are well-known ecological “reservoirs” for the fungus [21]. These rats live in burrows where the fungus thrives, and research shows a high concentration of the fungus in the soil around these burrows [21]. While handling these animals has been linked to infection in some cases, you do not need to have seen a rat to get sick; the spores can be in the dust or soil in areas where these animals live [22][19].

Validating the Experience

A diagnosis like this can be emotionally taxing. It is common to feel a sense of “medical trauma” due to the severity of the illness and the often long, confusing path to a correct diagnosis [23]. If you have visible skin lesions, you may also experience feelings of stigma or self-consciousness [1].

Know that these feelings are a normal response to a significant health event. Understanding that this was an environmental exposure—not something you “did” or something you can pass to your family—is a critical part of processing the diagnosis and moving toward recovery.

What To Do Now

  • Adhere to Follow-up: Keep all specialist appointments. Treating this infection requires months of careful monitoring.
  • Medication Safety: Do not stop or share any medicines without speaking to your doctor.
  • Seek Care if Worse: If you experience any worsening of symptoms, contact your care team immediately.

Common questions in this guide

What is talaromycosis, and what causes it?
Talaromycosis is a serious infection caused by the fungus Talaromyces marneffei. It can spread through the bloodstream and other parts of the body, especially when the immune system cannot control it.
Can I give talaromycosis to my family?
No. Talaromycosis is acquired from environmental spores and is not spread through casual contact, coughing, or sharing a home. Household members do not generally need preventive medication just because you have the infection, but they should discuss any personal risk with a clinician.
Who is most likely to develop severe talaromycosis?
Severe disease is most common in people with advanced HIV and very low CD4 counts, but it can also occur in people with other immune problems. Examples include autoimmune disease, organ or stem-cell transplantation, anti-interferon-gamma autoantibodies, and inherited immune conditions.
How do people become infected with Talaromyces marneffei?
People usually become infected by inhaling microscopic spores from soil, dust, or decaying vegetation in areas where the fungus naturally occurs. Bamboo rats can be a reservoir, but you do not need to have seen or handled one to be exposed.
Why is talaromycosis called a dimorphic fungal infection?
The fungus has two forms: a mold that grows in cooler environmental temperatures and a yeast form that grows in the warmer human body. This shape change helps it adapt inside the body and survive in immune cells, contributing to its ability to spread.
What immune tests might I need after a talaromycosis diagnosis?
Your clinician may evaluate for HIV, review your CD4 count, and consider testing for anti-interferon-gamma autoantibodies or other immune conditions. The exact evaluation depends on your history and helps your care team understand possible immune risk factors.
What follow-up is important after a talaromycosis diagnosis?
Treatment and recovery require months of follow-up and careful monitoring. Keep specialist appointments, take medicines only as directed, do not stop or share them without medical advice, and contact your care team promptly if symptoms worsen.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Talaromycosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my diagnosis, should I be tested for underlying conditions like HIV or anti-interferon-gamma autoantibodies?
  2. 2.Is my CD4 count a factor in my diagnosis, and how does it affect my risk?
  3. 3.Since this fungus is endemic to specific regions, are there precautions I should take if I travel or live in those areas?
  4. 4.Can you explain why talaromycosis is considered a 'dimorphic' fungus and how that influences my treatment?
  5. 5.What is the likelihood of a relapse, and what monitoring will I need long-term?
  6. 6.How do you typically address the emotional stress and potential stigma associated with a systemic fungal infection like this?

References

References (23)
  1. 1

    A global call for talaromycosis to be recognised as a neglected tropical disease.

    Narayanasamy S, Dat VQ, Thanh NT, et al.

    The Lancet. Global health 2021; (9(11)):e1618-e1622 doi:10.1016/S2214-109X(21)00350-8.

    PMID: 34678201
  2. 2

    Laboratory Maintenance and Growth of Talaromyces marneffei.

    Andrianopoulos A

    Current protocols in microbiology 2020; (56(1)):e97 doi:10.1002/cpmc.97.

    PMID: 32040264
  3. 3

    Validation of reference genes for real-time quantitative RT-PCR studies in Talaromyces marneffei.

    Dankai W, Pongpom M, Vanittanakom N

    Journal of microbiological methods 2015; (118()):42-50.

    PMID: 26327538
  4. 4

    MADS-Box Transcription Factor MadsA Regulates Dimorphic Transition, Conidiation, and Germination of Talaromyces marneffei.

    Wang Q, Du M, Wang S, et al.

    Frontiers in microbiology 2018; (9()):1781 doi:10.3389/fmicb.2018.01781.

    PMID: 30131782
  5. 5

    Macrophages protect Talaromyces marneffei conidia from myeloperoxidase-dependent neutrophil fungicidal activity during infection establishment in vivo.

    Ellett F, Pazhakh V, Pase L, et al.

    PLoS pathogens 2018; (14(6)):e1007063 doi:10.1371/journal.ppat.1007063.

    PMID: 29883484
  6. 6

    Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen.

    Cao C, Xi L, Chaturvedi V

    Mycopathologia 2019; (184(6)):709-720 doi:10.1007/s11046-019-00410-2.

    PMID: 31811603
  7. 7

    Cutaneous manifestations and dermoscopic findings are important clues to the diagnosis of Talaromyces marneffei in HIV patients with immune reconstitution inflammatory syndrome: A case report and literature review.

    Chaisuwannarak K, Chularojanamontri L, Junsuwan N, Eimpunth S

    The Journal of dermatology 2022; (49(1)):168-172 doi:10.1111/1346-8138.16197.

    PMID: 34651702
  8. 8

    Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing.

    Pruksaphon K, Intaramat A, Ratanabanangkoon K, et al.

    Diagnostic microbiology and infectious disease 2020; (96(3)):114959 doi:10.1016/j.diagmicrobio.2019.114959.

    PMID: 31836254
  9. 9

    Burden of Talaromyces marneffei infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis.

    Qin Y, Huang X, Chen H, et al.

    BMC infectious diseases 2020; (20(1)):551 doi:10.1186/s12879-020-05260-8.

    PMID: 32727383
  10. 10

    Talaromyces marneffei, Coccidioides species, and Paracoccidioides species-a systematic review to inform the World Health Organization priority list of fungal pathogens.

    Morris AJ, Kim HY, Nield B, et al.

    Medical mycology 2024; (62(6)) doi:10.1093/mmy/myad133.

    PMID: 38935909
  11. 11

    Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients.

    Chan JF, Lau SK, Yuen KY, Woo PC

    Emerging microbes & infections 2016; (5()):e19 doi:10.1038/emi.2016.18.

    PMID: 26956447
  12. 12

    Sequential Talaromyces marneffei and Legionella pneumophila infections leading to the diagnosis of anti-interferon-γ autoantibody-associated immunodeficiency: a case report.

    Yu M, Xiao Y, Liu Y, et al.

    BMC pulmonary medicine 2026; doi:10.1186/s12890-026-04455-0.

    PMID: 42464281
  13. 13

    Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity.

    Xing S, Zhang Z, Liu C, et al.

    Journal of clinical immunology 2024; (45(1)):17.

    PMID: 39325235
  14. 14

    Pulmonary Talaromycosis: A Window into the Immunopathogenesis of an Endemic Mycosis.

    Narayanasamy S, Dougherty J, van Doorn HR, Le T

    Mycopathologia 2021; (186(5)):707-715 doi:10.1007/s11046-021-00570-0.

    PMID: 34228343
  15. 15

    The novel Dbl homology/BAR domain protein, MsgA, of Talaromyces marneffei regulates yeast morphogenesis during growth inside host cells.

    Weerasinghe H, Bugeja HE, Andrianopoulos A

    Scientific reports 2021; (11(1)):2334 doi:10.1038/s41598-020-79593-4.

    PMID: 33504839
  16. 16

    Talaromyces marneffei Mp1p Is a Virulence Factor that Binds and Sequesters a Key Proinflammatory Lipid to Dampen Host Innate Immune Response.

    Sze KH, Lam WH, Zhang H, et al.

    Cell chemical biology 2017; (24(2)):182-194 doi:10.1016/j.chembiol.2016.12.014.

    PMID: 28111099
  17. 17

    Talaromyces marneffei promotes M2-like polarization of human macrophages by downregulating SOCS3 expression and activating the TLR9 pathway.

    Wei W, Ning C, Huang J, et al.

    Virulence 2021; (12(1)):1997-2012 doi:10.1080/21505594.2021.1958470.

    PMID: 34339354
  18. 18

    First-in-man observation of Talaromyces marneffei-transmission by organ transplantation.

    Hermans F, Ombelet S, Degezelle K, et al.

    Mycoses 2017; (60(3)):213-217 doi:10.1111/myc.12574.

    PMID: 27687582
  19. 19

    Genomic analysis provides insights into the transmission and pathogenicity of Talaromyces marneffei.

    Li Y, Luo H, Fan J, et al.

    Fungal genetics and biology : FG & B 2019; (130()):54-61 doi:10.1016/j.fgb.2019.05.002.

    PMID: 31075360
  20. 20

    Loop-mediated isothermal amplification coupled with a nanoparticle-based lateral biosensor for rapid, sensitive, and specific detection of Talaromyces marneffei.

    Zhou Y, Ye R, Wang Y, et al.

    Frontiers in microbiology 2025; (16()):1661312 doi:10.3389/fmicb.2025.1661312.

    PMID: 41262928
  21. 21

    Role of Rhizomys pruinosus as a natural animal host of Penicillium marneffei in Guangdong, China.

    Huang X, He G, Lu S, et al.

    Microbial biotechnology 2015; (8(4)):659-64 doi:10.1111/1751-7915.12275.

    PMID: 25824250
  22. 22

    Talaromyces Marneffei infections in five human immunodeficiency virus-negative patients with the history of predation on wild bamboo rats (Rhizomys spp) - a case series.

    Cao L, Sun Y, Zhou Z, Pan X

    BMC infectious diseases 2025; (25(1)):340 doi:10.1186/s12879-025-10713-z.

    PMID: 40069619
  23. 23

    Metagenomic next-generation sequencing for the early diagnosis of talaromycosis in HIV-uninfected patients: five cases report.

    Chen Q, Qiu Y, Zeng W, et al.

    BMC infectious diseases 2021; (21(1)):865 doi:10.1186/s12879-021-06551-4.

    PMID: 34425764

This page is for informational purposes only and does not constitute medical advice. Discuss your talaromycosis diagnosis, immune-system evaluation, treatment, and follow-up with your healthcare team.